Bacterial infection, airway and systemic inflammation and clinical outcomes before and after treatment of AECOPD, a longitudinal and cross-sectional study

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 12, Issue 1, 2015, Pages 19-30

  Chang, Chun ^a   Zhu, Hong ^a   Shen, Ning ^a   Chen, Yahong ^a   He, Bei ^a   Zhao, Jiangchao ^b   Yao, Wanzhen ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

CAT; COPD; Exacerbation; Health status; Resolution; Symptom

Indexed keywords

BUDESONIDE; C REACTIVE PROTEIN; INTERLEUKIN 6; IPRATROPIUM BROMIDE; PREDNISOLONE; SALBUTAMOL;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL CLEARANCE; BACTERIAL INFECTION; BACTERIAL LOAD; CANDIDA ALBICANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; ELISA KIT; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LIMIT OF DETECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; NEUTROPHIL; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFLAMMATION; SERRATIA MARCESCENS; SPUTUM ANALYSIS; SPUTUM CULTURE; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; CASE CONTROL STUDY; COMPLICATION; DISEASE COURSE; INFLAMMATION; LONGITUDINAL STUDY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ADULT; AGED; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84923076621     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.898043     Document Type: Article

References (92)

1. Baize S, Pannetier D, Oestereich L, et al: Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-1425
2. McElroy AK, Erickson BR, Flietstra TD, et al: Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerg Infect Dis 2014; 20:1683-1690
3. WHO Ebola Response Team: Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371:1481-1495
4. Leroy EM, Kumulungui B, Pourrut X, et al: Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575-576
5. Pourrut X, Souris M, Towner JS, et al: Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis 2009; 9:159
6. Leroy EM, Rouquet P, Formenty P, et al: Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004; 303:387-390
7. Feldmann H, Geisbert TW: Ebola haemorrhagic fever. Lancet 2011; 377:849-862
8. Georges AJ, Leroy EM, Renaut AA, et al: Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: Epidemiologic and health control issues. J Infect Dis 1999; 179(Suppl 1):S65-S75
9. Report of an International Commission: Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56:271-293
10. Harcourt BH, Sanchez A, Offermann MK: Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 1999; 73:3491-3496
11. Sanchez A, Geisbert TW, Feldmann H: Chapter 40. Filoviridae: Marburg and Ebola viruses. In: Fields Virology. Knipe DM, Howley PM (Eds). Fifth Edition. Philadelphia, PA, Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007
12. Wong G, Kobinger GP, Qiu X: Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 2014; 10:781-790
13. Hutchinson KL, Rollin PE: Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196(Suppl 2):S357-S363
14. Baize S, Leroy EM, Georges-Courbot MC, et al: Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5:423-426
15. Baize S, Leroy EM, Georges AJ, et al: Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128:163-168
16. Sanchez A, Lukwiya M, Bausch D, et al: Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78:10370-10377
17. McElroy AK, Erickson BR, Flietstra TD, et al: Ebola hemorrhagic fever: Novel biomarker correlates of clinical outcome. J Infect Dis 2014; 210:558-566
18. Bwaka MA, Bonnet MJ, Calain P, et al: Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis 1999; 179(Suppl 1):S1-S7
19. Schulte W, Bernhagen J, Bucala R: Cytokines in sepsis: Potent immunoregulators and potential therapeutic targets-an updated view. Mediators Inflamm 2013; 2013:165974
20. Mupere E, Kaducu OF, Yoti Z: Ebola haemorrhagic fever among hospitalised children and adolescents in northern Uganda: Epidemiologic and clinical observations. Afr Health Sci 2001; 1:60-65
21. Richards GA, Murphy S, Jobson R, et al: Unexpected Ebola virus in a tertiary setting: Clinical and epidemiologic aspects. Crit Care Med 2000; 28:240-244
22. Towner JS, Rollin PE, Bausch DG, et al: Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004; 78:4330-4341
23. Report of a WHO/International Study Team: Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ 1978; 56:247-270
24. Rowe AK, Bertolli J, Khan AS, et al: Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 1999; 179(Suppl 1):S28-S35
25. Bausch DG, Towner JS, Dowell SF, et al: Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007; 196(Suppl 2):S142-S147
26. Rodriguez LL, De Roo A, Guimard Y, et al: Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(Suppl 1):S170-S176
27. Centers for Disease Control and Prevention: Ebola virus disease (Ebola): Algorithm for evaluation of the returned traveler. 2014. Available at: http://www.cdc.gov/vhf/ebola/pdf/ebola-algorithm.pdf. Accessed October 14, 2014
28. Centers for Disease Control and Prevention: Epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus. Available at: http://www.cdc.gov/vhf/ebola/exposure/risk-factors-whenevaluating-person-for-exposure.html. Accessed October 30, 2014
29. Centers for Disease Control and Prevention: Ebola (Ebola virus disease): Information for health care workers and settings. Available at: http://www.cdc.gov/vhf/ebola/hcp/index.html. Accessed October 30, 2014
30. Public health Agency of Canada: Ebola virus disease (EVD)-health professionals. Available at: http://www.phac-aspc.gc.ca/id-mi/vhf-fvh/ebola-professionals-professionnels-eng.php. Accessed October 15, 2014
31. Canadian Critical Care Society, Canadian Association of Emergency Physicians, Association of Medical Microbiology & Infectious Diseases Canada: Ebola clinical care guidelines: A guide for clinicians in Canada. Interim report. Available at: http://www.ammi.ca/media/69846/Ebola%20Clinical%20Care%20Guidelines%202%20Sep%202014.pdf. Accessed October 19, 2014
32. Centers for Disease Control and Prevention: Preparing for Ebola: What U.S. hospitals can learn from Emory Healthcare and Nebraska Medical Center. Available at: http://emergency.cdc.gov/coca/transcripts/2014/call-transcript-101414.asp. Accessed October 18, 2014
33. Emory Healthcare: Emory Healthcare Ebola preparedness protocols. Available at: http://www.emoryhealthcare.org/ebola-protocol/ehcmessage.html. Accessed October 20, 2014
34. Centers for Disease Control and Prevention: Detailed hospital checklist for Ebola preparedness. Available at: http://www.cdc.gov/vhf/ebola/pdf/hospital-checklist-ebola-preparedness.pdf. Accessed October 15, 2014
35. Centers for Disease Control and Prevention: Safe management of patients with Ebola virus disease (EVD) in U.S. hospitals. Available at: http://www.cdc.gov/vhf/ebola/hcp/patient-management-us-hospitals.html. Accessed October 15, 2014
36. Centers for Disease Control and Prevention: Guidance on personal protective equipment to be used by healthcare workers during management of patients with Ebola virus disease in U.S. hospitals, including procedures for putting on (donning) and removing (doffing). Available at: http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe. Accessed October 23, 2014
37. Centers for Disease Control and Prevention: Infection prevention and control recommendations for hospitalized patients with known or suspected Ebola hemorrhagic fever in U.S. hospitals. Available at: http://www.cdc.gov/vhf/ebola/hcp/infection-prevention-and-control-recommendations.html. Accessed October 23, 2014
38. World Health Organization: Infection prevention and control guidance for care of patients in health-care settings, with focus on Ebola. Available at: http://apps.who.int/iris/bitstream/10665/130596/1/WHO_HIS_SDS_2014.4_eng.pdf?ua=1&ua=1&ua=1. Accessed October 15, 2014
39. Centers for Disease Control and Prevention: Interim guidance for specimen collection, transport, testing, and submission for patients with suspected infection with Ebola virus disease. Available at: http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-specimen-collection-submission-patients-suspected-infection-ebola.html. Accessed October 15, 2014
40. Centers for Disease Control and Prevention: Interim guidance for environmental infection control in hospitals for Ebola virus. Available at: http://www.cdc.gov/vhf/ebola/hcp/environmental-infection-control-in-hospitals.html. Accessed October 15, 2014
41. Centers for Disease Control and Prevention: Interim guidance for emergency medical services (EMS) systems and 9-1-1 public safety answering points (PSAPs) for management of patients with known or suspected Ebola virus disease in the United States. Available at: http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-emergency-medical-services-systems-911-public-safety-answering-points-management-patients-known-suspected-united-states.html. Accessed October 15, 2014
42. Centers for Disease Control and Prevention: Guidance on air medical transport for patients with Ebola virus. Available at: http://www.cdc.gov/vhf/ebola/hcp/guidance-air-medical-transport-patients.html. Accessed October 15, 2014
43. Olinger GG Jr, Pettitt J, Kim D, et al: Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012; 109:18030-18035
44. Geisbert TW, Lee AC, Robbins M, et al: Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 2010; 375:1896-1905
45. Qiu X, Wong G, Audet J, et al: Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53
46. Pettitt J, Zeitlin L, Kim do H, et al: Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013; 5:199ra113
47. World Health Organization: Ethical considerations for the use of unregistered interventions for Ebola viral disease; report of an advisory panel to WHO. Available at: http://apps.who.int/iris/bitstream/10665/130997/1/WHO_HIS_KER_GHE_14.1_eng.pdf. Accessed October 15, 2014
48. Mapp biopharmaceutical. Available at: http://www.mappbio.com/. Accessed October 15, 2014
49. Tekmira Pharmaceuticals Corporation: TKM-Ebola. Available at: http://www.tekmira.com/pipeline/tkm-ebola.php. Accessed October 15, 2014
50. Sarepta Therapeutics: AVI-7288 for treatment of marburg virus|sarepta therapeutics. Available at: http://www.sarepta.com/pipeline/avi-7288-marburg. Accessed October 15, 2014
51. BioCryst Pharmaceuticals: BCX4430. Available at: http://www.biocryst.com/bcx_4430. Accessed October 15, 2014
52. Chimerix: Brincidofovir (CMX001). Available at: http://www.chimerix.com/c/discovery-clinical-trials/brincidofovir.php. Accessed October 15, 2014
53. Food and Drug Administration: Investigational new drug (IND) application > emergency investigational new drug (EIND) applications for antiviral products. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm090039.htm. Accessed October 15, 2014
54. Health Canada: Drugs-special access to drugs and health products. Available at: http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php. Accessed October 15, 2014
55. Mupapa K, Massamba M, Kibadi K, et al: Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(Suppl 1):S18-S23
56. Sadek RF, Khan AS, Stevens G, et al: Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: Determinants of survival. J Infect Dis 1999; 179(Suppl 1):S24-S27
57. World Health Organization: Experimental therapies: Growing interest in the use of whole blood or plasma from recovered Ebola patients (convalescent therapies). Available at: http://www.who.int/mediacentre/news/ebola/26-september-2014/en/. Accessed October 14, 2014
58. World Health Organization: Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease. Available at: http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/. Accessed October 14, 2014
59. National Institute of Allergy and Infectious Diseases: NIH to launch human safety study of Ebola vaccine candidate. Available at: http://www.niaid.nih.gov/news/newsreleases/2014/Pages/EbolaVaxCandidate.aspx. Accessed October 15, 2014
60. Raghunathan K, Shaw A, Nathanson B, et al: Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med 2014; 42:1585-1591
61. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
62. Lurie N, Manolio T, Patterson AP, et al: Research as a part of public health emergency response. N Engl J Med 2013; 368:1251-1255
63. Dunning JW, Merson L, Rohde GG, et al; ISARIC Working Group 3, ISARIC Council: Open source clinical science for emerging infections. Lancet Infect Dis 2014; 14:8-9
64. ISARIC/WHO severe acute respiratory infection biological sampling study. Available at: http://www.prognosis.org/isaric. Accessed October 15, 2014
65. Healthcare Infection Control Practices Advisory Committee: 2007 Guideline for isolation precautions: Preventing transmission of infectious agents in healthcare settings. Available at: http://www.cdc.gov/hicpac/2007IP/2007ip_part2.html#e. Accessed October 16, 2014
66. Casado RJ, de Mello MJ, de Aragão RC, et al: Incidence and risk factors for health care-associated pneumonia in a pediatric intensive care unit. Crit Care Med 2011; 39:1968-1973
67. Paterson DL, Bonomo RA: Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005; 18:657-686
68. Burgner D, Dalton D, Hanlon M, et al: Repeated prevalence surveys of paediatric hospital-acquired infection. J Hosp Infect 1996; 34:163-170
69. Richards MJ, Edwards JR, Culver DH, et al: Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103:e39
70. Raymond J, Aujard Y: Nosocomial infections in pediatric patients: A European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol 2000; 21:260-263
71. Digiovine B, Chenoweth C, Watts C, et al: The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999; 160:976-981
72. Bigham MT, Amato R, Bondurrant P, et al: Ventilator-associated pneumonia in the pediatric intensive care unit: Characterizing the problem and implementing a sustainable solution. J Pediatr 2009; 154:582-587.e2
73. Turton P: Ventilator-associated pneumonia in paediatric intensive care: A literature review. Nurs Crit Care 2008; 13:241-248
74. Foglia EE, Fraser VJ, Elward AM: Effect of nosocomial infections due to antibiotic-resistant organisms on length of stay and mortality in the pediatric intensive care unit. Infect Control Hosp Epidemiol 2007; 28:299-306
75. Cosgrove SE: The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2):S82-89
76. McGrath EJ, Asmar BI: Nosocomial infections and multidrug-resistant bacterial organisms in the pediatric intensive care unit. Indian J Pediatr 2011; 78:176-184
77. Singhai M, Malik A, Shahid M, et al: A study on device-related infections with special reference to biofilm production and antibiotic resistance. J Glob Infect Dis 2012; 4:193-198
78. Magiorakos AP, Srinivasan A, Carey RB, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281
79. Multi-resistant Organisms: VICNISS Hospital Acquired Infection Surveillance Coordinating Centre. Available at: http://www.vicniss.org.au/Resources/HCWEducationModules/Module03MRO.pdf. Accessed August 5, 2013
80. Racaniello VR: Emerging infectious diseases. J Clin Invest 2004; 113:796-798
81. Septimus E: Clinician Guide-Blood Cultures: Centers for Disease Control and Prevention, 2012. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion. Available at: http://www.cdc.gov/getsmart/healthcare/learn-from-others/resources/clinician-guide.html. Accessed November 27, 2014
82. Shann F, Henning RJ, Shekerdemian L, et al: Unit RCsHMVIC. In: Paediatric Intensive Care Guidelines. Third Edition. Shann F (Ed). Parkville, VIC, Collective Pty, 2008, p 13
83. Duke T: Bronchioalveolar Lavage with the CombiCath 2013. Available at: http://vimeo.com/63143211. Accessed August 5, 2013
84. Meyer P, Rousseau H, Maillet JM, et al: Evaluation of blind nasotracheal suctioning and non-bronchoscopic mini-bronchoalveolar lavage in critically ill patients with infectious pneumonia: A preliminary study. Respir Care 2014; 59:345-352
85. Siegel JD, Rhinehart E, Jackson M, et al; Healthcare Infection Control Practices Advisory Committee: Management of multidrug-resistant organisms in healthcare settings 2006. Am J Infect Control 2007; 35(10 Suppl 2):S165-193
86. Sievert DMP, Ricks PP, Edwards JRMS, et al: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14
87. Antibiotics in the PICU [Protocol]. Parkville, VIC, 2011. Available at: http://www.rch.org.au/uploadedFiles/Main/Content/picu/Antibiotics_in_the_PICU[1].pdf. Accessed August 5, 2013
88. Grohskopf LA, Sinkowitz-Cochran RL, Garrett DO, et al; Pediatric Prevention Network: A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J Pediatr 2002; 140:432-438
89. Lodha R, Natchu UC, Nanda M, et al: Nosocomial infections in pediatric intensive care units. Indian J Pediatr 2001; 68:1063-1070
90. Simon A, Bindl L, Kramer MH: [Surveillance of nosocomial infections: Prospective study in a pediatric intensive care unit. Background, patients and methods]. Klin Padiatr 2000; 212:2-9
91. Banerjee SN, Grohskopf LA, Sinkowitz-Cochran RL, et al; National Nosocomial Infections Surveillance System; Pediatric Prevention Network: Incidence of pediatric and neonatal intensive care unit-acquired infections. Infect Control Hosp Epidemiol 2006; 27:561-570
92. Elward AM, Warren DK, Fraser VJ: Ventilator-associated pneumonia in pediatric intensive care unit patients: Risk factors and outcomes. Pediatrics 2002; 109:758-764